Journey Medical reports Q2 2026 results as Emrosi prescriptions climb
The dermatology company posted 23% revenue growth and narrowed its net loss as Emrosi prescriptions rose for a second straight quarter.
SEC filing
Latest
1 story
Sign inSign in1 story
The dermatology company posted 23% revenue growth and narrowed its net loss as Emrosi prescriptions rose for a second straight quarter.
SEC filing